319 related articles for article (PubMed ID: 31604081)
1. Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.
Solomon SS; Quinn TC; Solomon S; McFall AM; Srikrishnan AK; Verma V; Kumar MS; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Thomas DL; Sachdeva KS; Lucas GM; Mehta SH
J Hepatol; 2020 Jan; 72(1):67-74. PubMed ID: 31604081
[TBL] [Abstract][Full Text] [Related]
2. Respondent-driven sampling for identification of HIV- and HCV-infected people who inject drugs and men who have sex with men in India: A cross-sectional, community-based analysis.
Solomon SS; McFall AM; Lucas GM; Srikrishnan AK; Kumar MS; Anand S; Quinn TC; Celentano DD; Mehta SH
PLoS Med; 2017 Nov; 14(11):e1002460. PubMed ID: 29182638
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S
BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347
[TBL] [Abstract][Full Text] [Related]
4. Integrated HIV testing, prevention, and treatment intervention for key populations in India: a cluster-randomised trial.
Solomon SS; Solomon S; McFall AM; Srikrishnan AK; Anand S; Verma V; Vasudevan CK; Balakrishnan P; Ogburn EL; Moulton LH; Kumar MS; Sachdeva KS; Laeyendecker O; Celentano DD; Lucas GM; Mehta SH;
Lancet HIV; 2019 May; 6(5):e283-e296. PubMed ID: 30952565
[TBL] [Abstract][Full Text] [Related]
5. M
Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study.
McFall AM; Solomon SS; Lucas GM; Celentano DD; Srikrishnan AK; Kumar MS; Mehta SH
Addiction; 2017 Aug; 112(8):1480-1487. PubMed ID: 28317210
[TBL] [Abstract][Full Text] [Related]
7. Integration of a geospatially targeted community-based testing approach with respondent-driven sampling to identify people who inject drugs living with HIV and HCV in Patti and Gorakhpur, India.
Loeb TA; McFall AM; Srikrishnan AK; Anand S; Vasudevan CK; Mehta SH; Solomon SS
Drug Alcohol Depend; 2023 Jun; 247():109874. PubMed ID: 37087926
[TBL] [Abstract][Full Text] [Related]
8. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.
Solomon SS; Mehta SH; Srikrishnan AK; Solomon S; McFall AM; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Lucas GM; Kumar MS; Sulkowski MS; Quinn TC
Lancet Infect Dis; 2015 Jan; 15(1):36-45. PubMed ID: 25486851
[TBL] [Abstract][Full Text] [Related]
9. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
[TBL] [Abstract][Full Text] [Related]
10. Correlates of anti-hepatitis C positivity and use of harm reduction services among people who inject drugs in two cities in Croatia.
Handanagic S; Sevic S; Barbaric J; Dominkovic Z; Dakovic Rode O; Begovac J; Bozicevic I
Drug Alcohol Depend; 2017 Feb; 171():132-139. PubMed ID: 28088084
[TBL] [Abstract][Full Text] [Related]
11. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
[TBL] [Abstract][Full Text] [Related]
12. Has resourcing of non-governmental harm-reduction organizations in Ukraine improved HIV prevention and treatment outcomes for people who inject drugs? Findings from multiple bio-behavioural surveys.
Trickey A; Semchuk N; Saliuk T; Sazonova Y; Varetska O; Walker JG; Lim AG; Stone J; Vickerman P
J Int AIDS Soc; 2020 Aug; 23(8):e25608. PubMed ID: 32851812
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique.
Semá Baltazar C; Horth R; Boothe M; Sathane I; Young P; Chitsondzo Langa D; Condula M; Ricardo H; Dengo Baloi L; Cummings B; Schaad N; Gouveia L; Teodoro E; Raymond HF
BMC Infect Dis; 2019 Dec; 19(1):1022. PubMed ID: 31791273
[TBL] [Abstract][Full Text] [Related]
14. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
Fadnes LT; Aas CF; Vold JH; Ohldieck C; Leiva RA; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
BMC Infect Dis; 2019 Nov; 19(1):943. PubMed ID: 31703669
[TBL] [Abstract][Full Text] [Related]
15. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys.
Handanagic S; Bozicevic I; Civljak M; Dominkovic Z; Sevic S; Barbaric J; Nemeth Blazic T; Dakovic Rode O; Begovac J
Int J Drug Policy; 2016 Jun; 32():57-63. PubMed ID: 27160504
[TBL] [Abstract][Full Text] [Related]
16. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
17. Risky injection practices and HCV awareness in Chiang Mai Province, Thailand: a respondent-driven sampling study of people who inject drugs.
Prouté M; Le Coeur S; Tiv MH; Dub T; Jongpaijitsakul P; Ratnamhin A; Angkurawaranon C; Aramrattana A; Lallemant M
BMC Public Health; 2020 Sep; 20(1):1450. PubMed ID: 32972359
[TBL] [Abstract][Full Text] [Related]
18. Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco.
Mirzazadeh A; Chen YH; Lin J; Burk K; Wilson EC; Miller D; Veloso D; McFarland W; Morris MD
PLoS One; 2021; 16(4):e0249585. PubMed ID: 33798243
[TBL] [Abstract][Full Text] [Related]
19. Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs.
Tookes HE; Oxner A; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; McCollister K; Rodriguez A; Kolber MA; Chueng TA; Zayas S; McCoy B; Sutherland K; Archer C; Bartholomew TS
Trials; 2023 Feb; 24(1):96. PubMed ID: 36750867
[TBL] [Abstract][Full Text] [Related]
20. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
Midgard H; Finbråten AK; Malme KB; Berg-Pedersen RM; Tanum L; Olsen IC; Bjørnestad R; Dalgard O
Trials; 2020 Jun; 21(1):524. PubMed ID: 32539853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
